Gilead Says Patent, Antitrust Claims Over HIV Drug Fail

Law360, New York (March 23, 2016, 9:44 PM EDT) -- Gilead Sciences has asked a California federal judge to dismiss a patent and antitrust lawsuit over its new HIV treatment Genvoya, saying the AIDS Healthcare Foundation failed to identify any harm to competition or a real and immediate patent dispute.

Gilead, Japan Tobacco and Emory University urged the court in separate briefs Monday to dismiss the suit, saying the foundation failed to make a valid case for its claim that Gilead manipulated the patent approval process to keep a monopoly on drugs containing tenofovir.

"The complaint fails even to make out a legal claim that any patents are actually invalid," Gilead...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!